

Index

- ABHR. *See* alcohol-based hand rub
- ACA. *See* Affordable Care Act
- accrediting agencies, 417
- ACHs. *See* acute care hospitals
- Acinetobacter baumannii*, 27, 66, 95, 251–252, 258, 271
- ACIP. *See* Advisory Committee on Immunization Practices
- ACS NSQIP. *See* American College of Surgeons National Surgical Quality Improvement Program
- activism, individual, 427
- activities of daily living (ADLs), 229
- acute care hospitals (ACHs), LTCF and, 230
- acute hospitals, hand hygiene at, 87–89
- acute respiratory distress syndrome (ARDS), 140, 143
- acute surveillance, of MDROs, 182–183
- adenosine triphosphate (ATP), 66–67, 124–125
bioluminescence, 67
- ADLs. *See* activities of daily living
- administrators, meetings with, 26
- adverse events, 381–382
detecting, 382
noninfectious, 357–358
- Advisory Committee on Immunization Practices (ACIP), 325, 334, 337
- Affordable Care Act (ACA), 114
- Agency for Healthcare Research and Quality (AHRQ), 32, 66, 412
- AIIR. *See* airborne infection isolation room
- air handling systems, 401–403
in construction, 405
- airborne infection isolation room (AIIR), 53
- airborne precautions
empirical, 56
patient isolation, 53–55, 54
summary of, 54
- visitors and, 56
- alcohol, 157
as disinfectant, 63, 64
- alcohol-based hand rub (ABHR), 83, 85–86
application of, 86
for *C. difficile*, 86
dispenser locations, 86
efficacy of, 86
- all-inclusive catheter, 167
- altruism
defining, 8
Ebola and, 8
- AMA. *See* American Medical Association
- ambulatory care facilities, 239
- American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP), 151
- American Hospital Association, 30–31
- American Medical Association (AMA), code of ethics, 9
- American Society for Healthcare Risk Management (ASHRM), 32
- American Society for Quality (ASQ), 32
- American Society of Anesthesiologists (ASA), 150, 153–154
- American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE), 401
- Amherst, Jeffery, 316
- aminopenicillins, 202
- analyte-specific reagents (ASRs), 273
- anaphylactic reactions, CDC on, 119
- annual costs, determining, 26
- anthrax
attacks, 316
as bioterrorism agent, 317
cutaneous, 317
diagnosis, 291–300
prevention, 301–304
treatment, 306–312, 317
vaccines, 306–312
- antibiotic allergies, ASPs and, 219–220
- antibiotic exposure
as categorical variable, 49
definitions of, 49
- antibiotic resistance, 75. *See also* *specific organisms*
in LTCFs, 234–235
- antibiotic use
MDRGNs and, 195
unnecessary, 195
- anti-infective catheters, 137
- antimicrobial agents
grouping of, 49
HAIs and, 151
- antimicrobial cycling, ASPs and, 219
- antimicrobial lock solutions, 171
- antimicrobial prophylaxis, 157
- antimicrobial resistance
control group selection in, 48–49
NHSN on, 190
- antimicrobial stewardship programs (ASPs), 22, 24, 195, 213
- antibiotic allergies and, 219–220
- antimicrobial cycling and, 219
- behavior change and, 222–223
- C. difficile* and, 207–208
- CDC on, 218
- core principles of, 218
- durations of therapy and, 217
- effects of, 220
- formulary restrictions, 216
- implementation, 215–220
- institutional guidelines, 215–216
- interventions, 215–220
- laboratories and, 281
- mandatory, 281
- non-traditional settings, 221–222
- organization of, 213–215
- outcome measures, 220
- outcomes, 220–221
- populations studied by, 103
- prescriber-level interventions, 218–219
- prior authorization, 216
- process measures, 220, 221
- prospective audits, 216–218
- surveillance for, 94–97
- targets of, 215–220
- transitions of care and, 220
- antimicrobial susceptibility testing (AST), 275
- antimicrobial use and resistance (AUR), 103
- antiretrovirals, 355–356
- anti-vaccine movement, 4
- APIC. *See* Association for Professionals in Infection Control and Epidemiology
- Apisarnthanarak, A., 168
- ARDS. *See* acute respiratory distress syndrome
- ASA. *See* American Society of Anesthesiologists
- ASHRAE. *See* American Society of Heating, Refrigerating and Air-Conditioning Engineers
- ASHRM. *See* American Society for Healthcare Risk Management
- Aspergillus*, 95, 124, 387, 389, 401, 407
- ASPR. *See* Assistant Secretary of Preparedness and Response
- ASPs. *See* antimicrobial stewardship programs
- ASQ. *See* American Society for Quality
- ASRs. *See* analyte-specific reagents
- Assistant Secretary of Preparedness and Response (ASPR), 287, 288
- Association for Professionals in Infection Control and Epidemiology (APIC), 10, 232, 251
- Association for the Advancement of Medical Instrumentation, 74
- Association of peri-Operative Nurses, 74

- Association of Value Analysis Professionals, 18
- AST. *See* antimicrobial susceptibility testing
- asymptomatic bacteriuria, 134
- atelectasis, 143
- ATP. *See* adenosine triphosphate
- attack rate, 42
- Aum Shinrikyo, 316, 319
- AUR. *See* antimicrobial use and resistance
- automated identification, 274–275
- automated monitoring systems, 84
- automatic surveillance, 114–115
- autonomy, 3
- defining, 7
- Ebola and, 7
- justice and, 3
- B. anthracis*, 317
- bacille Calmette-Guerin (BCG), 373
- bacterial infections, in resource-limited settings, 252–256
- bacteriuria, 133, 134, 136–137
- asymptomatic, 134
- symptomatic, 134
- barrier precautions
- for *C. difficile*, 206–207
- CLABSI and, 167
- construction and, 406
- for MDROs, 181
- BCA. *See* business case analysis
- BCG. *See* bacille Calmette-Guerin
- behavior change, antimicrobial stewardship programs and, 222–223
- Belay, E. D., 74
- benchmarking, 383–384
- beneficence, 3, 6–7
- Ebola and, 7–8
- maximizing, 7–8
- best practices, 2, 3
- CLABSI and, 166
- bias
- defining, 45
- differential, 45
- in epidemiological methods, 45
- misclassification, 48–49
- nondifferential, 45
- biofilms, 66
- on urinary catheters, 133
- biological disasters, 287
- agents of, 315
- clinical presentation in, 291–300
- clues to, 314–315
- diagnosis in, 291–300
- early identification of, 305–315
- Ebola as, 320
- epidemiologist in, 288, 291
- H1N1 influenza as, 321–322
- infection prevention in, 288–289
- Middle East Respiratory Syndrome as, 322
- novel influenza as, 321
- pandemic influenza as, 321
- prevention issues, 301–304
- reporting requirements, 315
- risk communication in, 305
- SARS as, 320–321
- surveillance in, 288–289
- Bion, J., 168
- Biopreparat, 316
- BioSense, 315
- bioterrorism agents, 75, 315–316
- anthrax as, 317
- botulinum toxin as, 319–320
- category A, 316
- most likely, 316–320
- plague as, 319
- smallpox as, 317–319
- tularemia as, 319
- viral hemorrhagic fever as, 320
- bloodborne pathogens, 128
- nosocomial infections, 256
- post-exposure management of, 260
- post-exposure prophylaxis for, 351–353
- in resource-limited settings, 260
- bloodstream infection (BSI), 93, 98. *See also specific types*
- CAUTI and, 134
- diagnosis of, 165
- Bordetella pertussis*, 326–331
- exposure workup, 340
- laboratory evaluation, 350
- transmission of, 340
- botulinum toxin
- as bioterrorism agent, 319–320
- diagnosis, 291–300
- prevention, 301–304
- treatment, 306–312
- vaccines, 306–312
- Bouam, S., 152
- bovine spongiform encephalopathy (BSE), 338
- BPN. *See* brain natriuretic peptide
- brain biopsy, 74–75
- brain natriuretic peptide (BPN), 144
- Brazil, 252, 260
- BSE. *See* bovine spongiform encephalopathy
- BSI. *See* bloodstream infection
- budgetary considerations, laboratories and, 282
- Buehler, S. S., 274
- bug-drug mismatches, 217
- bundles
- CLABSI, 36
- IHI on, 36
- process measures and, 36
- Burke, J. P., 152
- business case analysis (BCA), 23, 24–25
- defining, 24
- financial benefits in, 27
- health benefits in, 27
- making cases in, 27
- program expansion and, 25
- service expansion and, 25
- C. difficile* infection (CDI), 5–6, 31, 66, 68, 89, 95, ix, 206–207, 273
- ABHR for, 86
- antimicrobial stewardship, 207–208
- asymptomatic, 208
- aversion of infections, 20–21
- barrier precautions for, 206–207
- clindamycin and, 207–208
- clinical manifestations, 202
- community-associated, 205
- contact precautions for, 55
- contamination, 73
- decontamination for, 207
- defining, 201
- diagnosis, 204
- environment and, 72–73
- epidemiology of, 201–202
- fidaxomicin for, 203–204
- gold standard, 203
- hand hygiene, 206–207
- healthcare facility-onset, 205
- history, 201
- IDSA on, 203
- indeterminate onset, 205
- infection rates, 20–21
- in LTCF, 233–234
- metronidazole for, 204
- outbreaks, 208
- pathophysiology, 202
- prevention, 72–73, 205–206, 208
- rates of, 220
- recurrent, 205
- risk factors, 202
- SHEA on, 203
- spores, 73
- spread of, 201
- surveillance, 205
- transmission of, 72, 73
- treatment, 203–205
- UVGI for, 20, 21
- vancomycin for, 203–204
- Canadian Critical Care Trials Group, 143–144
- Canadian Nosocomial Infection Surveillance Program, 205–206
- Canadian Task Force on Preventive Healthcare, 87
- Candida*, 134, 271–272
- carbapenem-resistant *Enterobacteriaceae* (CRE), 58, 119, 123, 190, 191–192, 196, 213, 252–256
- CDC on, 192
- duodenoscopes and, 65–66
- carbapenem-resistant *Klebsiella pneumoniae*, 64, 123
- Cardo, D. M., 103–104
- Cartter, M. L., 336
- case definition, in outbreaks, 121
- case finding
- difficulties in, 121–123
- in outbreaks, 121–123
- case reports, in epidemiology, 43
- case series, in epidemiology, 43
- case-control studies
- control group selection and, 48–49
- as epidemiological methods, 44
- nested, 44
- in outbreaks, 125
- patient selection in, 44
- summary of, 44
- VRE in, 44
- case-finding methods
- for HAIs, 109–110
- selection of, 111
- catheter hubs, 167
- catheter-associated bloodstream infection (CVC-BSI), 163
- incidence of, 253–254
- catheter-associated urinary tract infections (CAUTIs), 133
- acquisition of, 133
- BSI and, 134
- descriptive epidemiology in, 133–134
- diagnosis of, 134–135
- general strategies, 135
- incidence of, 252, 253–254
- microbial etiology of, 134
- NHSN on, 135
- organisms associated with, 133, 134
- prevention of, 135–137
- prevention teams, 35
- quality improvement and, 35
- rates of, 22
- risk factors, 134
- specific strategies, 135
- stakeholders and, 35
- surveillance of, 134–135
- catheter-related bloodstream infection (CRBSI), 163
- CAUTIs. *See* catheter-associated urinary tract infections
- CBA. *See* cost benefit analysis
- CCNA. *See* cell culture cytotoxicity neutralization assay
- CDC. *See* Centers for Disease Control and Prevention
- CDI. *See* *C. difficile* infection
- CDSS. *See* computer-assisted decision support systems
- CEA. *See* cost effectiveness analysis
- cefazolin, 23–24
- ceilings, construction of, 404

Index

- cell culture cytotoxicity
neutralization assay
(CCNA), 203, 204
- Centers for Disease Control and Prevention (CDC), 5, 18–19, 30–31, 32, 36–37, 58, 147, 150, 190, 213, 238, 351, 364, 411–412
- on anaphylactic reactions, 119
- on ASPs, 218
- on construction, 393
- on contact precautions, 55
- on CRE, 192
- Epicenters, 144
- oversight and, 412–417
- on patient isolation, 52–53
- Patient Notification Toolkit, 128
- reporting to, 271, 272
- risk index, 150
- on SARS, 342
- on surveillance, 93
- on tuberculosis, 364–365, 372
- on VAEs, 142
- Centers for Medicare and Medicaid Services (CMS), 21, 22, 32, 36–37, 114, 124, 135, 229–230
- on CLABSI, 163
- on oversight, 417
- participation in, 22
- surveillance and, 149
- surveys, 420
- central line-associated bloodstream infection (CLABSI), ix, 162, 252
- addressing, 25–26
- analysis of, 165–166
- barrier precautions, 167
- best practice measures, 166, 168
- bundles, 36
- catheter choice and, 167
- catheter types, 163–164
- chlorhexidine and, 171
- CMS on, 163
- costs of, 26
- CVC insertion and, 167
- defining, 164–165
- diagnosing, 165
- education, 168
- epidemiology of, 162–163
- hand hygiene and, 167
- history, 163
- implementation of preventive measures, 168
- impregnated catheters, 171
- measures after insertion, 167
- measures before insertion, 167
- measures during insertion, 167
- mortality, 162
- nosocomial, 257
- prevention of, 26–27
- preventive measures, 166–168
- rates of, 22, 165–166
- reduction of, 26
- risk factors, 164
- skin antiseptics, 167
- surveillance, 164
- technology and material measures, 166
- terminology, 163
- training, 168
- ultrasound in, 167, 171
- central venous catheters (CVCs), 162
- CLABSI and, 167
- subclavian vein for, 167
- cephalosporins, 202
- certified safety and health officials (CSHOs), 422
- Cesarean section, 150
- CF. *See* cystic fibrosis
- CFIR. *See* Consolidated Framework of Implementation Research
- CFR. *See* Code of Federal Regulations
- Chalfine, A., 152
- Challenger, 380
- channel scopes, 69–72
- chart review. *See also* 100% chart review
- total, 110, 111
- chemical agents
- for disinfection, 60–61
- for high-level disinfection, 60–61
- for sterilization, 60–61
- chemotherapy, 361
- CHICA-Canada. *See* Community and Hospital Infection Control Association – Canada
- children, VAE in, 142
- China, 319
- chlorhexidine, 142–143, 171, 180
- CLABSI and, 171
- for MDRGNs, 195
- for MDROs, 184
- ciprofloxacin, 306–312
- CJD. *See* Creutzfeldt-Jakob disease
- CLABSI. *See* central line-associated bloodstream infection
- Clark County, 334
- Classen, D., 107
- cleaning
- assessment of, 124–125
- HAI and, 67–68
- monitoring, 66–67
- in United States, 66–67
- Climo, M., 184
- clindamycin, 202
- C. difficile* and, 207–208
- Clinical and Laboratory Standards Institute (CLSI), 190, 281
- clinical microbiologists, 281–282
- clinical trials
- on disinfection, 70–71
- hydrogen peroxide, 70–71
- ultraviolet irradiation, 70–71
- clinical ward rounds, HAIs and, 110–111
- clonality, 280–281
- CLSI. *See* Clinical and Laboratory Standards Institute
- CMA. *See* cost minimization analysis
- CMS. *See* Centers for Medicare and Medicaid Services
- coagulase-negative staphylococci (CoNS), 162, 165
- Code of Federal Regulations* (CFR), 412
- Coffey, C. C., 371
- cohort studies
- as epidemiological methods, 44–45
- in outbreaks, 125
- prospective, 44–45
- retrospective, 44–45
- colon cancer, screening, 24
- colonization pressure, MDRGNs and, 194–195
- Columbia, 380
- commercial interests, 418
- common commensals, 275
- communications, in outbreaks, 127–128
- Community and Hospital Infection Control Association – Canada (CHICA-Canada), 10
- community assets, 9
- compliance rates, 27–28
- comprehensive unit safety program (CUSP), 33
- computer-assisted decision support systems (CDSS), 218
- computer-based surveillance, 114–115
- confidence intervals, 95%, 46–47
- confidentiality, 3, 3, 127
- conflicts of interest, ethics and, 2, 3
- confounding
- defining, 45
- in epidemiological methods, 45
- CoNS. *See* coagulase-negative staphylococci
- conscientious practice, Ebola and, 9–10
- Consolidated Framework of Implementation Research (CFIR), 168
- construction
- air handling systems in, 405
- barrier precautions and, 406
- CDC on, 393
- of ceilings, 404
- commissioning, 398–401
- costs of, 407–408
- of counter tops, 405
- errors in, 388
- final check, 407
- of floors, 404
- guidelines, 389, 390–391
- health risks, 389
- HICPAC on, 393
- infection prevention permit, 397
- IP in, 387–388
- of isolation rooms, 403
- Joint Commission on, 393
- PPE and, 404
- of protective environments, 403
- resources for, 389
- schematic design phase of, 401–402
- site monitoring tools, 397–398
- standards, 390–391
- storage areas and, 407
- traffic patterns and, 406–407
- of walls, 404–405
- construction-related infections
- organisms causing, 388–389
- persons at risk, 388
- constructive feedback, 216–217
- Consumer's Union (CU), 418
- contact precautions, 181
- for *C. difficile*, 55
- CDC on, 55
- discontinuation of, 182
- empirical, 56
- patient isolation, 54, 55
- summary of, 54
- unintended effects of, 56
- visitors and, 56
- control group selection
- in antimicrobial resistance, 48–49
- case-control studies and, 48–49
- difficulties in, 48–49
- misclassification bias in, 48–49
- control populations, 24–25
- Cornia, P. B., 136
- coronary artery bypass graft surgery, 23
- cost benefit analysis (CBA), 23, 24
- cost effectiveness
- product evaluation and, 20–21
- of UVGI, 21
- World Health Organization on, 24
- cost effectiveness analysis (CEA), 23
- cost minimization analysis (CMA), 23, 23
- cost reductions, 24
- cost utility analysis (CUA), 23, 24

- cough etiquette, in outpatient setting, 241
- counter tops, construction of, 405
- CRBSI. *See* catheter-related bloodstream infection
- CRE. *See* carbapenem-resistant *Enterobacteriaceae*
- Creutzfeldt-Jakob disease (CJD), 1, 326–331
- defining, 73, 337–338
- exposure workups, 337–338
- iatrogenic, 73–74
- inactivation of, 73–75
- inheritance of, 73–74
- prevention, 338
- variant, 338
- cross-sectional studies, as epidemiological methods, 44
- Cryptococcus neoformans*, 273
- CSHOs. *See* certified safety and health officials
- CU. *See* Consumer's Union
- CUA. *See* cost utility analysis
- cumulative incidence
- defining, 42
- incidence rate and, 42–43
- CUSP. *See* comprehensive unit safety program
- cutaneous anthrax, 317
- CVC-BSI. *See* catheter-associated bloodstream infection
- CVCs. *See* central venous catheters
- cystic fibrosis (CF), in outpatient settings, 246
- Cystic Fibrosis Foundation, 246
- cystoscopes, 69–72
- cytotoxin, 202
- daily activities, ethical dilemmas in, 1
- daily defined dose (DDD), 105, 220
- daily practice, ethics and, 1
- daily working groups, 214
- data
- analysis, in surveillance, 106–107
- cost and outcome, 27–28
- evaluation, exposure workups and, 333
- management, surveillance, 106
- organization, outbreaks and, 123
- in product evaluation, 19–20
- reporting, LIS and, 276
- validation of, 101
- data collection, 27–28
- exposure workups and, 332, 333
- outbreaks and, 123, 125
- in surveillance, 105–106
- data sources
- for HAIs, 107–108
- SSI, 153–154
- for surveillance, 107–108
- days of therapy (DOT), 105, 220–221
- DDD. *See* daily defined dose
- decolonization
- defining, 184
- of MDRGNs, 195
- for MDROs, 184
- methods, 195
- for outbreaks, 184
- decontamination
- hydrogen peroxide for, 68
- no touch methods, 68
- no touch methods of, 72–73
- ultraviolet light for, 68
- deep-incisional SSIs, 148
- Delgado-Rodriguez, M., 152
- Deming, W. Edwards, 30
- Deming's cycle, 33–34
- DePalo, V. A., 168
- Department of Health and Human Services (DHHS), 287, 288
- Department of Labor, 18
- descriptive epidemiology
- in CAUTIs, 133–134
- in UTIs, 133–134
- developing countries, surveillance in, 113–114
- device exposure, surveillance and, 113
- DHHS. *See* Department of Health and Human Services
- dialysis, 16
- dialysis centers
- as outpatient setting, 245–246
- standard precautions at, 245
- diarrhea, 208
- Diehl, William, on ethics, 10
- differential bias, 45
- diphtheria, vaccine, 352–353
- diphtheroids, 275
- direct observation, with
- technology assistance, 83, 84
- dirt, 405–406
- dirty-to-clean flow, 61
- discriminatory power, 280, 281
- disease distribution, 41
- disease frequency, 41
- measures of, 41
- disease transmission, environment in, 66
- disinfectants, 58
- alcohol as, 63, 64
- high-touch objects and, 67–68
- hydrogen peroxide as, 63, 64
- iodophors as, 63, 64
- monitoring, 66–67
- noncritical items and, 64
- peracetic acid as, 63, 64
- phenolics as, 63, 64
- quaternary ammonium compounds as, 63, 64
- semicritical items and, 61–64
- sodium hypochlorite as, 63, 64
- disinfection
- assessment of, 124–125
- chemical agents for, 60–61
- clinical trials on, 70–71
- critical items, 58–61
- of endoscopes, 64–65
- exposure investigation after, 69
- failures, 68
- high-level, 60–61
- HPV and, 68–69
- improving, 67–68
- low-level, 59
- methods for, 59
- in outpatient setting, 243
- rational approach to, 58
- in resource-limited settings, 261
- risks, 68
- dispenser locations, 86
- distance, 105
- diuretics, 144
- DMAIC, 33–34
- Donabedian, Avedis, 35–36
- DOT. *See* days of therapy
- doxycycline, 313
- droplet precautions
- empirical, 56
- patient isolation, 54, 55
- summary of, 54
- visitors and, 56
- drug use evaluation (DUE), 221
- drugs, clinical efficacy of, 20
- DUE. *See* drug use evaluation
- duodenoscopes
- contamination of, 66
- CRE and, 65–66
- durations of therapy, 221
- ASPs and, 217
- dust, 405–406
- duty to care, 9, 9
- dynamic population, prevalence in, 41–42
- E. coli*, 47–48, 134, 194
- transmission of, 195
- E. faecium*, 177
- Ebola, 93, 243, 261
- altruism and, 8
- autonomy and, 7
- as biological disasters, 320
- conscientious practice and, 9–10
- ethical dilemmas, 7–10
- exposure workups, 343
- justice and, 8
- nonmaleficence and, 8
- outbreaks, 252
- patient isolation and, 55
- solidarity and, 9
- transmissibility of, 8
- utility and, 8
- in West Africa, 8
- ECF. *See* extended care facilities
- ecologic studies, as epidemiological method, 43–44
- economic evaluation
- differential valuation, 23
- types of, 23
- economic incentives, 22–23
- ectoparasites, exposure workups, 340
- Edmond, M. B., 7
- education, 259
- CLABSI, 168
- exposure workups and, 332–333
- hand hygiene, 88
- laboratories and, 282–283
- MDROs, 182
- post-exposure prophylaxis, 357
- tuberculosis, 368
- effectivity, quality improvement and, 31
- efficiency, quality improvement and, 31
- Eggimann, P., 168
- EHR. *See* electronic health records
- EIA. *See* enzyme immunoassay
- Elastoplast, 407
- electronic health records (EHR), 217, 218
- electronic surveillance, 114–115
- of SSIs, 152
- Electronic Surveillance System for the Early Notification of Community-Based Epidemics (ESSENCE), 315
- emerging pathogens, 75
- exposure workups, 341
- in outpatient setting, 243
- post-exposure prophylaxis and, 358
- in resource-limited settings, 260–261
- encephalopathy, 4
- endoscopes, 204. *See also* duodenoscopes
- contamination of, 66
- disinfection of, 64–65
- reprocessing of, 64–65
- sterilization of, 64–65
- endoscopic retrograde cholangiopancreatography (ERCP), 58, 66
- end-stage renal disease, 245
- Enguidanos, R., 334
- enteric flora, 64–65
- Enterobacteriaceae*, 52
- Enterobacteriaceae*, UTIs from, 133
- Enterococcus*, 206
- enterotoxin, 202
- Enterovirus D68, 75
- environment
- C. difficile* and, 72–73
- in disease transmission, 66
- MDRGNs and, 194
- role of, 72–73
- environmental control, in patient isolation, 53

Index

- environmental management
services representative, 16
- environmental measures, for MDROs, 182
- Environmental Protection Agency (EPA), 72, 75, 412
quarantine exemptions, 74
- enzyme immunoassay (EIA), 121, 203, 204
- EPA. *See* Environmental Protection Agency
- epidemic curve, of outbreaks, 123
- epidemiologic ethics, 3
- epidemiological methods
bias in, 45
cohort studies as, 44–45
confounding in, 45
cross-sectional studies, 44
ecologic studies, 43–44
measures of effect in, 45–46
measures of strength of association in, 46–47
quasi-experimental study design in, 47–48
randomized controlled trials as, 45
special issues in, 47–48
value of, 41
- epidemiologists
in biological disasters, 288, 291
financial support for, 22–23
knowledge of, ix
resources of, ix
skills of, ix
- epidemiology, ix
of *C. difficile*, 201–202
case reports in, 43
case series in, 43
of CLABSI, 162–163
defining, 41
descriptive, 133–134
evolution of, 31
multidisciplinary collaborations and, 31, 32
of nosocomial infections, 252–256
of rubella, 335
study design, 43
- equitability, quality improvement and, 31
- ERCP. *See* endoscopic retrograde cholangiopancreatography
- Erickson, Douglas, 407
- errors, reducing, 33
- ESBL-EK. *See* extended-spectrum β -lactamase-producing *E. coli* and *Klebsiella* species
- ESCMID. *See* European Society of Clinical Microbiology and Infectious Diseases
- ESKAPE pathogens, 271, 274
- ESSENCE. *See* Electronic Surveillance System for the Early Notification of Community-Based Epidemics
- ethical dilemmas
approaches to, 3
in daily activities, 1
- Ebola virus, 7–10
infection prevention and, 2, 3, 4
taxonomy of, 1–3, 2
vaccination and, 3–5
- ethics, 1
AMA code of, 9
codes of, 10
conflicts of interest and, 2, 3
daily practice and, 1
defining, 1
Diehl on, 10
epidemiologic, 3
exposure and, 1
infection prevention and, 1
information disclosure and, 2, 3
medical, 3
overlooking, 1
person-oriented, 3
population-oriented, 3
professionalism and, 2, 3
resource allocation and, 2, 3
from theory to practice of, 10–11
- ethylene oxide (ETO), 58–61, 66
advantages and disadvantages of, 62
- ETO. *See* ethylene oxide
- EUCAST. *See* European Committee on Antimicrobial Susceptibility Testing
- European Committee on Antimicrobial Susceptibility Testing (EUCAST), 190
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID), 190, 196
- evidence-based measures, 259
- expertise
deference to, 34
hierarchy and, 32
regulating, 425
- exposure, ethics and, 1
- exposure workups, 325–332
administration mandates for, 332
agents causing, 326–331
Bordetella pertussis, 340
Creutzfeldt-Jakob disease, 337–338
data collection and, 332, 333
data evaluation and, 333
- Ebola, 343
- ectoparasites, 340
- education and, 332–333
- emerging pathogens, 341
- group A *Streptococcus*, 340
- healthcare workers and, 332
- hepatitis A virus, 336–337
- influenza, 337
- lice, 340–341
- measles, 334
- Middle East Respiratory Syndrome, 342–343
- Mycobacterium tuberculosis*, 338–339
- N. meningitidis*, 339–340
- occupational health and, 332
- parvovirus B19, 336
- policies and procedures, 332
- rubella, 334–335
- SARS, 342
- scabies, 341
- smallpox, 341–342
- varicella zoster, 333–334
- extended care facilities (ECF), tuberculosis, 368
- extended-spectrum β -lactamase-producing *E. coli* and *Klebsiella* species (ESBL-EK), 49, 271
- extended-spectrum β -lactamases (ESBLs), 190–191
- extensively drug-resistant tuberculosis (XDR-TB), 361
- Facilities Guidelines Institute (FGI), 387, 389–393
- facility maintenance, 16
- failure modes and effects analysis (FMEA), 383–384, 385
- F-A-S-T, 367
- FCS. *See* fetal calf serum
- FDA. *See* Food and Drug Administration
- febrile pulmonary syndrome (FPS), early identification of, 305–314
- febrile rash syndrome (FRS), early identification of, 314
- fecal microbiota transplantation (FMT), 204
- fetal calf serum (FCS), 64
- FGI. *See* Facilities Guidelines Institute
- fidaxomicin, for *C. difficile*, 203–204
- Filatov-Dukes Disease, 336
- financial impacts, 27
- FiO₂. *See* fraction of inspired oxygen
- floors, construction of, 404
- fluoroquinolones, 47–48, 234
- FluSurge, 321
- FMEA. *See* failure modes and effects analysis
- FMT. *See* fecal microbiota transplantation
- Food and Drug Administration (FDA), 58, 366
product evaluation and, 20
- food services, 16
- formulary restrictions, of ASPs, 216
- FPS. *See* febrile pulmonary syndrome
- fraction of inspired oxygen (FiO₂), 141, 142
- freedom of contact, 3
- freedom of movement, 3
- frequency matching, 125
- FRS. *See* febrile rash syndrome
- FTE. *See* full-time employees
- full surveys, 420
- full-time employees (FTE), 26
- fully automated surveillance, 105
- Fusarium*, 389
- Gandra, S., 7
- Gap Analysis, 25
- gastric acid, 72
- gastroenteritis, LTCFs, 233
- gastrointestinal tract infections, 229
in LTCFs, 233–234
- GDH. *See* glutamate dehydrogenase
- general ventilation, tuberculosis and, 369
- Geneva Protocol, 316
- genitourinary tract dysfunction, 232–233
- gloves
for MDROs, 181
in transmission-based precautions, 54
universal use, 183–184
- glutamate dehydrogenase (GDH), 203, 204
- glutaraldehyde, 60–61
- glycolaldehydes, 133
- gowns
for MDROs, 181
in patient isolation, 53
in transmission-based precautions, 54
universal use, 183–184
- GRADE system, 87
- gram-negative bacteria, 4
- graphical displays, 107
- group A *Streptococcus*, exposure workups, 340
- Guerin, K., 168
- Guillain-Barre syndrome, 351
- H1N1 influenza, 243, 305–306, 412–417
as biological disaster, 321–322
- HAC. *See* Hospital-Acquired Conditions
- HAIs. *See* healthcare-associated infections
- Haley, R. W., 150
- hand hygiene, 259
at acute hospitals, 87–89
adherence to, 83, 84–85, 88
barriers to, 88
for *C. difficile*, 206–207
CLABSI and, 167

- dispenser locations, 86
 education, 88
 equipment, 87–88
 facilities, 403
 feedback on, 88–89
 framework, 82–83
 guidelines, 82
 healthcare workers and, 82, 88
 history of, 30
 implementation, 86–87, 262
 improvement strategies, 87
 intelligent systems, 83
 Joint Commission on, 87
 measurement of, 83
 moments for, 82–83
 monitoring, 83
 multi-step, 83–85
 patient isolation and, 53
 performing, 88
 product consumption, 83
 product selection, 85–86, 87
 quality improvement and, 30
 in resource-limited settings, 261–262
 SHEA on, 87
 technique, 83–85
 tolerability of, 86
 World Health Organization on, 82–83
- Harris, A. D., 5, 7
 Hawthorne Effect, 83
 HCAHPS. *See* Hospital Consumer Assessment of Healthcare Providers and Systems
 HCP. *See* healthcare precautions
 HCWs. *See* healthcare workers
 HE. *See* healthcare epidemiology
 Health and Human Services (HHS), 412
 Health Insurance Portability and Accountability Act (HIPAA), 127
 healthcare, value in, 31–32
 healthcare epidemiology (HE), 92, 96–97
 Healthcare Infection Control Practices Advisory Committee (HICPAC), 52, 114, 156, 180, 196, 325, 338, 412–417
 on construction, 393
 healthcare precautions (HCP), 56
 healthcare professionals, in patient isolation, 56
 healthcare workers (HCWs), 1, 3, 361
 compliance of, 261
 cultures of, 279
 exposure workups and, 332
 hand hygiene and, 82, 88
 MDRGNs and, 193–194
 in outpatient setting, 244–245
 protection, 23
 screening, 278
- surveillance of, 351
 tuberculosis and, 367
 vaccinations for, 352–353
 healthcare workers, LTBI and, 367
 healthcare-associated infections (HAIs), 22, 92, 107, 177
 antimicrobial agents and, 151
 case-finding methods, 109–110
 cleaning and, 67–68
 clinical ward rounds and, 110–111
 costs of, 24
 data sources for, 107–108
 defining, 104
 frequency of, ix
 hospital-wide surveillance and, 108
 identifying, 105
 impact of, 93
 IP on, 103
 laboratory report review and, 110
 mortality rates from, ix
 NHSN on, 103
 objective-based surveillance and, 109
 outbreak thresholds, 109
 patient labeling, 106
 prevalence of, 108
 prevention of, 30, ix, 258
 priority-based surveillance and, 109
 quality improvement and, 30
 rates, 112
 in resource-limited settings, 251
 risk factors, 252
 spectrum of pathogens, 271, 272
 SSIs, 104
 surveillance for, 94–97, 108
 targeted surveillance of, 109
 total chart review and, 110
 HEICS. *See* Hospital Emergency Incident Command System
 Henderson, 355
 HEPA. *See* high-efficiency particulate air
 hepatitis A virus, 326–331
 exposure workups, 336–337
 transmission of, 336
 vaccine, 337, 352–353
 hepatitis B virus, 1, 240
 control measures, 354
 criteria for exposure, 353
 laboratory evaluation, 350
 post-exposure prophylaxis, 353–354
 testing for, 245–246
 transmission of, 5, 353
 vaccination for, 5
 vaccine, 352–353
 hepatitis C virus, 240
 control measures, 355
 exposure criteria, 354
 post-exposure prophylaxis, 354–355
 testing for, 245–246
 transmission, 354
 Herwaldt, Loreen, ix
 HHS. *See* Health and Human Services
 HICPAC. *See* Healthcare Infection Control Practices Advisory Committee
 HICS. *See* Hospital Incident Command System
 high reliability organizations (HROs), 32–33
 failures of, 32
 high reliability tools, quality improvement and, 33–34
 high-efficiency particulate air (HEPA), 53
 high-level disinfection, 59
 chemical agents for, 60–61
 in outpatient setting, 243–244
 high-touch objects, disinfectants and, 67–68
 HIPAA. *See* Health Insurance Portability and Accountability Act
 HIV. *See* human immunodeficiency virus
 home health nurse, 16
 Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS), 22
 Hospital Emergency Incident Command System (HEICS), 287–288
 Hospital Incident Command System (HICS), 287–288
 Hospital Preparedness Program (HPP), 287, 288
 Hospital-Acquired Conditions (HAC), 22, 114
 hospitals
 dimensions of, 33
 limitations of, 32–33
 surveys of, 33
 hospital-wide surveillance, 96–97
 HAIs and, 108
 HPP. *See* Hospital Preparedness Program
 HPV. *See* human papilloma virus
 HROs. *See* high reliability organizations
 human immunodeficiency virus (HIV), 1
 consultation, 356
 exposure criteria, 355
 personnel-to-patient transmission and, 356–357
 post-exposure prophylaxis, 355–357
 SHEA on, 356–357
 transmission, 355
 human papilloma virus (HPV)
 disinfection and, 68–69
 sterilization and, 68–69
 hydrogen peroxide, 60–61
 advantages and disadvantages of, 62
 clinical trials, 70–71
 for decontamination, 68
 as disinfectant, 63, 64
 improved, 60–61
 ozone and, 62
 ultraviolet irradiation compared with, 68
 vaporized, 62
 hydrogen peroxide gas plasma, advantages and disadvantages of, 62
 Hyle, E. P., 49
 hyperglycemia, 157
 hypothermia, 157
- ICRA. *See* Infection Control Risk Assessment
 Idaho, 26
 IDSA. *See* Infectious Diseases Society of America
 IGRAs. *See* interferon gamma release assays
 IHI. *See* Institute for Healthcare Improvement
 imipenemase metallo- β -lactamase (IMP), 191–192
 immediate use steam sterilization (IUSS), 244
 immersion, perfusion compared with, 69–72
 immunization
 laboratory evaluation and, 350
 preplacement examination, 350
 immunoprophylaxis, 351
 IMP. *See* imipenemase metallo- β -lactamase
 impregnated catheters, CLABSI, 171
 incidence, 42–43
 cumulative, 42
 defining, 42
 measurement of, 42
 of nosocomial infections, 42
 incidence rate, defining, 42
 India, 258
 indirect cost, in product evaluation, 21
 individual activism, 427
 Industrial Revolution, 30
 indwelling urinary catheterization, 135, 136
 alternatives to, 136
 infection, surgical site. *See* surgical site infection
 infection, surveillance. *See* surveillance
 infection control committee, 13, 258–259
 administrative functions of, 15
 benchmark compliance of, 14

Index

- infection control (cont.)
 chair of, 14–15
 drafting policies, 14
 guidelines, 14
 infection prevention team
 and, 13
 meeting minutes, 15
 meeting practices, 15
 membership, 13
 patient safety and, 384
 reports, 16
 responsibilities of, 13, 14
 role and functions of,
 13–14
 infection control networks
 international, 262–263
 in resource-limited settings,
 262–263
 sponsorship of, 262, 263
 infection control observations,
 in outbreaks, 123–125
 Infection Control Risk
 Assessment (ICRA), 387
 completion of, 393–397
 matrix, 395, 399
 team development, 393
 team notification, 393–397
 infection prevention (IP),
 153–154
 assessments, 107
 in biological disasters,
 288–289
 in construction, 387–388
 on definitions, 104
 ethical dilemmas and, 2, 3, 4
 ethics and, 1
 on HAIs, 103
 molecular typig and,
 279–280
 personnel, 1
 in renovation, 387–388
 SSI, 113, 155
 staff goals, 155
 on surveillance, 105
 universal principles of, 239
 infection prevention and
 control (IPC), 230
 administration, 232
 development of, 231–232
 LTCF, 231
 policies and practices, 232
 regulations, 231–232
 infection prevention regulation
 history of, 411–412
 impact of, 419
 organizational policies, 426
 rational, 426–427
 stakeholders in, 418–419
 infection prevention regulations
 implications of, 423–425
 MDROs and, 422–423
 infection prevention team,
 infection control
 committee and, 13
 infection preventionists, 16
 infection rates
 observed, 104
 overall, 112
 infection-related ventilator-
 associated complication
 (IVAC), 141
 infection-related ventilators, 98
 Infectious Diseases Society of
 America (IDSA), 156, 171,
 214, 230–231, 351
 on *C. difficile*, 203
 on tuberculosis, 372–373
 influenza, 326–331
 exposure workups, 337
 H1N1, 243, 305–306,
 321–322, 412–417
 impact of, 321
 in LTCF, 233
 novel, 321
 pandemic, 291–300, 301–304,
 306–312, 321
 vaccines, 337, 352–353
 influenza vaccine, 5, 105
 information collection, in
 surveillance, 98
 information disclosure, ethics
 and, 2, 3
 information technology, patient
 safety and, 385
 INICC. *See* International
 Nosocomial Infection
 Control Consortium
 injection safety, in outpatient
 setting, 240–241
 Inpatient Prospective Payment
 System (IPPS), 114
 Inpatient Quality Reporting
 Program (IQR), 114, 423
 Institute for Healthcare
 Improvement (IHI), 32
 on bundles, 36
 Institute of Medicine (IOM), 31,
 370–371, 380–381
 institutional guidelines, of ASPs,
 215–216
 intensive care units, 24,
 133–134, 162, 235
 interferon gamma release assays
 (IGRAs), 233, 259–260
 International Federation of
 Infection Control, 262, 263
 International Nosocomial
 Infection Control
 Consortium (INICC),
 162–163. *See also*
 nosocomial infections
 intraoperative intervention,
 SSIs, 157
 invasive procedures, 58
 iodophors, as disinfectants, 63,
 64
 IOM. *See* Institute of Medicine
 IP. *See* infection prevention
 IPC. *See* infection prevention
 and control
 IPPS. *See* Inpatient Prospective
 Payment System
 IQR. *See* Inpatient Quality
 Reporting Program
 isolation. *See* patient isolation
 isoniazid, 373
 IUSS. *See* immediate use steam
 sterilization
 IVAC. *See* infection-related
 ventilator-associated
 complication
 Japan, 30
 Joint Commission, 18, 22,
 30–31, 32, 69, 114, 411–412
 on construction, 393
 on hand hygiene, 87
 infection control standards,
 14
 on patient safety, 384–385
 on RCA, 382–383
 on renovation, 393
 survey, 420–421
 Juran, Joseph M., 30
 justice, 3
 defining, 8
 Ebola and, 8
K. pneumoniae, 191–192
 Kaldjian, L. C., 3, 4
 Kelly, C. P., 334
 KISS. *See* Krankenhaus
 Infektions-Surveillance
 System
Klebsiella pneumoniae, 110, 133,
 194
 transmission of, 195
 Kollef, M., 177–178
 Krankenhaus Infektions-
 Surveillance System
 (KISS), 164–165
 LabID Event module, 205
 laboratories, 271
 advisories, 281–282
 ASPs and, 281
 automated identification,
 274–275
 budgetary considerations
 and, 282
 education and, 282–283
 organism detection, 273–274
 outbreak detection and,
 276–277
 specimen collection and
 transport, 271–272
 specimen evaluation,
 272–273
 supplementary cultures,
 277–279
 in surveillance, 271
 susceptibility testing,
 274–275
 laboratory evaluation
Bordetella pertussis, 350
 hepatitis B virus, 350
 immunization and, 350
 of isolates in outbreaks,
 125–126
 measles, 350
 mumps, 350
 rubella, 350
 serologic screening and, 350
 varicella, 350
 laboratory information system
 (LIS), 275
 data reporting and, 276
 laboratory report review, HAIs
 and, 110
 laboratory representatives, 16
 Laboratory Response Network
 (LRN), 317
 Lactobacillus, 204–205
 LAIV. *See* live attenuated
 influenza vaccines
 laryngoscope, 69
 latent system errors, 382
 latent tuberculosis infection
 (LTBI), 367
 healthcare workers and,
 367
 testing, 368
 treatment of, 372–374
 leadership
 characteristics of, 33
 quality improvement and, 33
 Lean, 33
 Leapfrog Group, 419
 Legionella, 94, 95, 105, 273, 387,
 388–389, 401
 length of stay, surveillance and,
 112
 length of therapy (LOT),
 220–221
 Lessler, J., 105
 lice, 326–331
 exposure workups, 340–341
 Lin, W. C., 110
 linen, in patient isolation, 53
 LIS. *See* laboratory information
 system
 live attenuated influenza
 vaccines (LAIV), 337
 local exhaust ventilation,
 tuberculosis and, 369
 long-term acute care hospitals
 (LTACHs), 195–196,
 221–222, 235
 challenges of, 222
 importance of, 229
 long-term care facility (LTCF),
 177, 195–196, 221–222, 235
 acute care hospitals compared
 with, 230
 antibiotic resistance in,
 234–235
C. difficile in, 233–234
 frequent care transitions in,
 231
 gastroenteritis in, 233
 gastrointestinal tract
 infections in, 233–234
 influenza in, 233
 IPC and, 231
 outbreaks in, 229
 pneumonia in, 233
 policies and practices in, 232
 pressure ulcers in, 234
 resources, 230
 respiratory tract infections in,
 233

- risks in, 230
 scabies in, 234
 skin infections in, 234
 soft tissue infections in, 234
 surveillance in, 232
 tuberculosis in, 233
 UTIs in, 232–233
- long-term care unit
 representatives, 16
- LOT. *See* length of therapy
- low-level disinfection, 59
 advantages and disadvantages of, 63, 64
- LRN. *See* Laboratory Response Network
- LTACHs. *See* long-term acute care hospitals
- LTBI. *See* latent tuberculosis infection
- LTCF. *See* long-term care facility
- Lui, S. L., 336
- Maki, D., 165
- Malawi, 260
- MALDI-TOF. *See* matrix-assisted laser desorption/ionization time of flight
- mandatory practices, 425
- Mantoux method, 367–368
- MAP. *See* mean airway pressure
- Marra, A. R., 168
- masks
 for MDROs, 181
 in patient isolation, 53
 in transmission-based precautions, 54
- matched studies, 125
- matrix-assisted laser desorption/ionization time of flight (MALDI-TOF), 214, 274
- MBI-LCBI. *See* mucosal barrier injury laboratory-confirmed bloodstream infection
- McFarland, L. V., 206
- McGeer criteria, 230, 232
- McGuckin, M. B., 109
- MDR. *See* multidrug-resistance
- MDRGNs. *See* multidrug-resistant gram-negative bacteria
- MDROs. *See* multidrug-resistant organisms
- MDR-TB. *See* multidrug-resistant tuberculosis
- mean airway pressure (MAP), 142
- measles
 exposure workups, 334
 laboratory evaluation, 350
 in outpatient setting, 243
 vaccines, 334, 352–353
- mecA*, 178, 214
- mecC*, 178
- media, outbreaks and, 128
- medical devices, clinical efficacy of, 20
- medical errors, 380–381
- medical ethics, 3
- medical records, 123
 urinary catheters and, 136
- Medicare severity diagnosis related groups (MS-DRG), 22
- medico-legal concerns, in
 outbreaks, 127
- Memnoniella*, 389
- meningococcus, vaccines, 352–353
- mercury gas bulbs, 68
- meta-analysis, 165
- methicillin-resistant
Staphylococcus aureus (MRSA), 5, 10, 27, 66, 82, 95, 156, 177, 213, 214, 217–218, 234, 271–272
- contact precautions, 7
- control of, 6
- incidence rate of, 106
- mechanism of resistance, 178–180
- patient isolation for, 6, 56
- prevention of, 184
- risk factors, 6
- screening, 183
- sources, 126
- spread of, 5–6
- surveillance, 275
- transmission, 178–180
- metronidazole, for *C. difficile*, 204
- Mexico, 256
- MIC. *See* minimum inhibitory concentration
- microbial colonization, 3
- microbial contamination, extent of, 149
- microbial etiology
 of CAUTIs, 134
 of UTIs, 134
- microbiologists, 16
- Middle East Respiratory Syndrome, 7–10, 75, 93, ix, 243, 252, 325, 412–417
 as biological disaster, 322
 diagnosis, 291–300
 exposure workups, 342–343
 prevention, 301–304
- Miller, L., 168
- minimum inhibitory concentration (MIC), 178–180
- misclassification bias, in control group selection, 48–49
- molecular typing
 general principles, 280–281
 IP and, 279–280
 for nosocomial infections, 280, 281
- morbidity, VAE, 141
- mortality, of tularemia, 319
- mortality rates, 92
 CLABSI, 162
 from healthcare-associated infections, ix
- VAE, 141
- MRSA. *See* methicillin-resistant *Staphylococcus aureus*
- MS-DRG. *See* Medicare severity diagnosis related groups
- mucosal barrier injury
 laboratory-confirmed bloodstream infection (MBI-LCBI), 165
- multidisciplinary
 collaborations,
 epidemiology and, 31, 32
- multidisciplinary teams, 215
- multidrug-resistance (MDR), 65
 in resource-limited settings, 257–258
- multidrug-resistant
Acinetobacter baumannii, 192
- multidrug-resistant gram-negative bacteria (MDRGNs), ix, 190, 234
 antibiotic use and, 195
 causal factors, 193
 chlorhexidine for, 195
 colonization pressure and, 194–195
 decolonization of, 195
 defining, 190
 environment and, 194
 faculty reservoirs, 195–196
 guidelines, 196
 healthcare workers and, 193–194
 important, 190–193
 in resource-limited settings, 258
 transmission of, 193–195
- multidrug-resistant organisms (MDROs), 92, 276
 acute surveillance, 182–183
 barrier precautions, 181, 411
 chlorhexidine for, 184
 control measures, 180, 185
 decolonization, 184
 education, 182
 environmental measures for, 182
 equipment in, 181–182
 gloves for, 181
 gowns for, 181
 impact of, 93
 infection prevention
 regulations and, 422–423
 masks for, 181
 patient isolation for, 181–182
 practice settings, 184–185
 prevalence of, 177–178
 risk assessment, 180
 screening, 183
 significance of, 177–178
 surveillance for, 94–97, 180–181, 275–276
- multidrug-resistant tuberculosis (MDR-TB), 361
- multi-step testing strategies, 204
- mumps, 326–331
- incidence of, 335
- laboratory evaluation, 350
- vaccines, 334, 335, 352–353
- mupirocin, 180, 184–185
- Mycobacterium tuberculosis*, 52, 256, 326–331, 401
 exposure workup, 338–339
 prevention, 259–260, 339
 in resource-limited settings, 259–260
- Myers, M. G., 361
- N. meningitidis*
 exposure workups, 339–340
 transmission of, 340
- N95 respirators, 322, 371, 372
- NAAT. *See* nucleic acid amplification tests
- National Committee for Quality Assurance (NCQA), 32
- National Health and Nutrition Examination Survey (NHANES), 86
- National Healthcare Safety Network (NHSN), 22, 27–28, 103, 107, 162–163
 on antimicrobial resistance, 190
 on CAUTIs, 135
 functions of, 111–112
 goals of, 111–112
 on HAIs, 103
 participants in, 111–112
 reporting to, 133
 surveillance and, 111–112
 on UTIs, 134–135
 on VAP, 140
- National Incident Management Structure (NIMS), 287–288
 creation of, 287
 implementation, 288
- National Inpatient Survey (NIS), 233–234
- National Institute for Occupational Safety and Health (NIOSH), 55
- National Nosocomial Infection Survey (NNIS), 103, 111, 235
 on SSIs, 254
- National Patient Safety Foundation (NPSF), 32, 385
- National Quality Foundation (NQF), 32
- National Surgical Quality Improvement Program (NSQIP), 147–148, 150–151
- NC SPICE. *See* North Carolina Statewide Program for Infection Control and Epidemiology
- NCQA. *See* National Committee for Quality Assurance
- NDM. *See* New Delhi metallo- β -lactamase
- needlestick injuries, 21

Index

- Needlestick Safety Prevention Act of 2000, 18
- Neisseria meningitidis*, 326–331
- neonates, VAE in, 142
- neurological syndromes (NS), early identification of, 314
- neurosurgical instruments, 74–75
- New Delhi metallo- β -lactamase (NDM), 191–192
- NHANES. *See* National Health and Nutrition Examination Survey
- NHs. *See* nursing homes
- NHSN. *See* National Healthcare Safety Network
- Nichol, K. L., 335–336
- Nichols, R. L., 150–151
- NIMS. *See* National Incident Management Structure
- 95% confidence intervals, 46–47
- NIOSH. *See* National Institute for Occupational Safety and Health
- NIS. *See* National Inpatient Survey
- NNIS. *See* National Nosocomial Infection Survey
- no touch methods of decontamination, 68, 73
- noncritical items
- disinfectants and, 64
 - sterilization and, 64
- nondifferential bias, 45
- noninfectious adverse events, 357–358
- nonmaleficence, 3, 6–7
- defining, 8
 - Ebola and, 8
- nontuberculous mycobacteria, 124
- norovirus, 66
- North Carolina Statewide Program for Infection Control and Epidemiology (NC SPICE), 239
- nosocomial infections, 30–31, 72–73
- bloodborne pathogens, 256
 - CLABSI, 257
 - epidemiology of, 252–256
 - historical rates of, 42
 - incidence of, 42
 - molecular typing for, 280, 281
 - in resource-limited settings, 252–256
 - tuberculosis, 362, 363–364
- novel influenza, as biological disaster, 321
- NPSF. *See* National Patient Safety Foundation
- NQF. *See* National Quality Foundation
- NS. *See* neurological syndromes
- NSQIP. *See* National Surgical Quality Improvement Program
- nuclear weapons, 316
- nucleic acid amplification tests (NAAT), 372
- nursing homes (NHs), 229
- objective-based surveillance, 96–97
- HAI and, 109
- observed rates of infection, 104
- occupational health and safety, 16
- establishing programs, 259
 - exposure workups and, 332
 - in outpatient setting, 244–245
- Occupational Safety and Health Administration (OSHA), 53–55, 370, 371, 412
- Blood-borne Pathogens Standard, 31, 244–245
- Needlestick Safety Prevention Act, 18
- on oversight, 417–418
 - regulations, 371–372
 - survey, 422
 - on tuberculosis, 370–371
- odds ratio, 46
- risk and, 45
- Office of Inspector General (OIG), 412
- Olson, R., 335–336
- 100% chart review
- of high risk patients, 150–151
 - of selected procedures, 149–150
- SSIs, 148–149
- OPA. *See* ortho-phthalaldehyde
- OPAT. *See* outpatient antimicrobial therapy
- organizational culture, quality improvement and, 33
- organizational resources, 426
- organ-space SSIs, 148
- ortho-phthalaldehyde (OPA), 60–61
- OSHA. *See* Occupational Safety and Health Administration
- outbreak thresholds, HAIs, 109
- outbreaks, 13–14
- analytic studies, 125
 - automated detection of, 120
 - C. difficile*, 208
 - case definition, 121
 - case finding in, 121–123
 - case-control studies in, 125
 - cohort studies in, 125
 - common causes of, 122
 - communications in, 127–128
 - considerations during, 127
 - data collection and, 123, 125
 - data organization and, 123
 - decolonization for, 184
 - detecting, 119–120
 - early detection of, 276
 - Ebola, 252
 - epidemic curve of, 123
 - evolution of, 119
 - immediate first steps, 120–121
- infection control
- observations in, 123–125
 - intervention implementation, 127
 - investigation steps, 120, 277
 - laboratory detection, 276–277
 - laboratory evaluation of isolates, 125–126
 - in LTCFs, 229
 - media and, 128
 - medico-legal concerns in, 127
 - patient notifications in, 127–128
 - in resource-limited settings, 256
 - sources of, 123
 - spot maps of, 123
 - tuberculosis, 361
- outcome measures
- advantages of, 37
 - of ASPs, 220
 - defining, 36–37
 - process measures compared with, 37
 - quality improvement and, 36–37
 - stakeholders and, 37
- outpatient antimicrobial therapy (OPAT), 164
- outpatient setting, 238
- cough etiquette in, 241
 - dialysis centers, 245–246
 - disinfection in, 243
 - emerging pathogens in, 243
 - employee health in, 244–245
 - hand hygiene in, 239–240
 - high-level disinfection in, 243–244
 - injection safety in, 240–241
 - measles in, 243
 - occupational health and safety in, 244–245
 - organizational considerations, 238–239
 - personal protective equipment in, 240
 - respiratory hygiene in, 241
 - screening in, 241–242
 - for special populations, 245–247
 - standard precautions in, 239
 - sterilization in, 244
 - surface decontamination in, 241
 - transmission-based precautions, 241
 - tuberculosis in, 242–243
- outpatient settings, CF in, 246
- oversight, 412
- CDC and, 412–417
 - CMS on, 417
 - governmental agencies with, 413–416
 - OSHA on, 417–418
 - state governments on, 418
- ozone, hydrogen peroxide and, 62
- P. aeruginosa*, 49, 95, 123–124, 133, 134, 194, 258, 271
- resistance, 106–107
- P* value, 46
- defining, 46
 - limitations of, 46
- Palomar, M., 168
- pandemic influenza, 306–312
- as biological disaster, 321
 - diagnosis, 291–300
 - preparedness, 321–322
- PAPRs. *See* powered air-purifying respirators
- Parkland Health and Hospital System, 421–422
- partial surveys, 420
- parvovirus B19, 326–331
- exposure workup, 336
- patient days (PD), 220–221
- patient discharge, 106
- SSIs and, 151
 - in tuberculosis, 374
- patient harm, 32–33
- patient isolation, 1, 5–7
- airborne precautions, 53–55, 54
 - CDC on, 52–53
 - contact precautions, 54, 55, 181
 - discontinuing, 56
 - droplet precautions, 54
 - Ebola and, 55
 - empirical institution of, 55–56
 - environmental control in, 53
 - foregoing, 56
 - gloves in, 53
 - gown in, 53
 - hand hygiene and, 53
 - healthcare professionals in, 56
 - importance of, 52
 - linen in, 53
 - masks in, 53
 - for MDROs, 181–182
 - for MRSA, 6, 56
 - patient placement in, 53
 - patient resuscitation in, 53
 - patient-care equipment in, 53
 - requirements in, 53
 - rooms for, 403
 - sharp devices in, 53
 - standard precautions, 53, 181
 - systems, 52, 52
 - transmission-based precautions, 53
 - for tuberculosis, 55
 - unintended effects of, 56
 - visitors and, 56
 - for VRE, 6, 56
- patient labeling, in HAIs, 106
- Patient Notification Toolkit, 128
- patient notifications, in outbreaks, 127–128
- patient placement, in patient isolation, 53
- patient resuscitation, in patient isolation, 53

- patient safety, 380–381
 implementing, 385
 improving, 384
 infection control committee and, 384
 information technology and, 385
 Joint Commission on, 384–385
 terminology, 381
- patient-care equipment, in patient isolation, 53
- patient-centeredness, quality improvement and, 31
- pay-for-performance, 423, 425–426
- PCAST. *See* President's Council of Advisors on Science and Technology
- PCR. *See* polymerase chain reaction
- PD. *See* patient days
- PDSA, 33–34
- Pediatric Infectious Diseases Society (PIDS), 214
- PEEP. *See* positive end expiratory pressure
- penicillin, 213
 allergies, 219
Penicillium, 389
- PEP. *See* post-exposure prophylaxis
- peptide nucleic acid fluorescent in situ hybridization (PNA-FISH), 273
- peracetic acid, 58–61, 60–61
 as disinfectants, 63, 64
- Peredo, R., 168
- Perez, F., 168
- perfusion, immersion compared with, 69–72
- perineum, 133
- period prevalence, 41
- peripheral venous catheters (PVCs), 163–164
 infection risk from, 34
 quality improvement and, 34
- peripherally inserted central catheters (PICC), 163, 164
- personal protective equipment (PPE), 260–261, 289, 290–291, 321
 construction and, 404
 indications for, 240
 in outpatient setting, 240
- personal respiratory protection, tuberculosis and, 370–372
- personnel-to-patient transmission, HIV and, 356–357
- pertussis vaccine, 4, 352–353
 side effects of, 4
- PFGE. *See* pulsed-field gel electrophoresis
- pharmacist, 16
- pharmacy and therapeutics (P&T), 214, 216
- phenolics, as disinfectants, 63, 64
- physical therapy, in outpatient setting, 246–247
- PICC. *See* peripherally inserted central catheters
- PIDS. *See* Pediatric Infectious Diseases Society
- Pittet, D., 82
- plague
 as bioterrorism agent, 319
 diagnosis, 291–300
 prevention, 301–304
 treatment, 306–312
 vaccines, 306–312
- Plasmodium*, 273
- plumbing, 403–404
- PNA-FISH. *See* peptide nucleic acid fluorescent in situ hybridization
- pneumonia, 142–143
 in LTCF, 233
- point prevalence, 41
- Polgreen, P. M., 335
- polymerase chain reaction (PCR), 121, 203, 204, 214, 273–274
- populations
 ASP studying, 103
 surveillance, 101–105
- portable air filtration units, tuberculosis and, 369
- positive end expiratory pressure (PEEP), 141
- possible ventilator-associated pneumonia (PVAP), 141, 142
- post-antibiotic era, 185, 319
- postdischarge surveillance, 111
 SSI, 151–152
- post-exposure prophylaxis (PEP), 340
 for bloodborne pathogens, 351–353
 consultation, 356
 education, 357
 emerging pathogens and, 358
 hepatitis B virus, 353–354
 hepatitis C virus, 354–355
 HIV, 355–357
 orientation, 357
 programs, 355–356
 recommendation for, 356
 regimens, 357
- postoperative infection, 152
- postoperative intervention, SSIs, 157
- postsurgical wound infection, 381–382
- “The Power of the Positive No” (Ury), 25
- powered air-purifying respirators (PAPRs), 53–55, 322, 372
- PPE. *See* personal protective equipment
- pregnancy, vaccination and, 4–5
- preoperative intervention, SSIs, 156–157
- preplacement examination
 immunization, 350
 serologic screening, 350
- prescriber-level interventions, of ASPs, 218–219
- President's Council of Advisors on Science and Technology (PCAST), 22
- pressure ulcers, in LTCFs, 234
- prevalence, 41–42, 112
 defining, 41
 in dynamic population, 41–42
 of HAIs, 108
 period, 41
 point, 41
 surveillance of, 108
 survey, 96–97
- prions, 59, 74. *See also specific diseases*
 agents, 1
 sterilization and, 74
- prior authorization, ASPs and, 216
- priority-based surveillance, HAIs and, 109
- problem framing, 26
- procedure-specific rates, SSI, 154
- process measures
 advantages of, 36
 of ASPs, 220, 221
 bundles and, 36
 defining, 36
 outcome measures compared with, 37
 of quality improvement, 36
 stakeholders and, 37
 surveillance for, 113
- product evaluation, 18
 assessment of, 20
 cost effectiveness and, 20–21
 data in, 19–20
 FDA and, 20
 financial impact analysis in, 20
 indirect cost in, 21
 information gathering in, 19
 plans, 19
 post-implementation monitoring, 20
 priorities in, 19
 product selection in, 20
 production information in, 19
 selection criteria in, 19
 steps in, 18–20
 surveys, 19
 team organization in, 19
 value analysis and, 18
- product volume, 84
- professional societies, 426–427
- professionalism, ethics and, 2, 3
- program expansion, BCA and, 25
- Pronovost, P., 168
- prospective audits, of ASPs, 216–218
- prospective cohort studies, 44–45
- protective environments, construction of, 403
- Proteus*, 133
- proton-pump inhibitors, 208
- Providencia*, 133
- pseudomembranous colitis, 201
- P&T. *See* pharmacy and therapeutics
- public health model, 3
 local departments for, 418
- public health representatives, 16
- public health surveillance, 315
- public reporting, quality improvement and, 31
- puerperal fever, 30, 92
- pulsed-field gel electrophoresis (PFGE), 126, 194, 280–281
- PVAP. *See* possible ventilator-associated pneumonia
- PVCs. *See* peripheral venous catheters
- pyuria, 135
- QALY. *See* quality-adjusted life years
- quality assurance and performance improvement (QAPI), 231–232
- quality improvement
 CAUTIs and, 35
 effectivity and, 31
 efficiency and, 31
 equitability and, 31
 HAIs and, 30
 handwashing and, 30
 high reliability tools and, 33–34
 history of, 30, 31
 implementation of, 34–35
 leadership and, 33
 measurement of, 35–36
 organizational culture and, 33
 outcome measures and, 36–37
 patient-centeredness and, 31
 process measures of, 36
 public reporting and, 31
 PVCs and, 34
 safety and, 31
 stakeholders views on, 32
 success of, 34
 sustainability of, 35
 timeliness and, 31
 transparency and, 31
 websites, 32
- quality of care, 36
- quality-adjusted life years (QALY), 23–24
- quasi-experimental study design
 advantages of, 47
 defining, 47
 in epidemiological methods, 47–48
 limitations of, 47

Index

- quaternary ammonium compounds, as disinfectants, 63, 64
- Rajneeshees, 316
- randomized controlled trials, as epidemiological methods, 45
- rapid tests, 274
- RCA. *See* root cause analysis
- Rea, E., 5
- Real-Time Outbreak and Disease Surveillance (RODS), 315
- Reason, James, 33, 382
- regulatory requirements, surveillance and, 114
- reimbursement, 425–426
- relative risk, 45–46
- renovation
 - guidelines, 390–391
 - IP in, 387–388
 - Joint Commission on, 393
 - resources for, 389
 - standards, 390–391
- reprocessing
 - of endoscopes, 64–65
 - guidelines, 65–66
 - personnel, 66
- reproducibility, 280, 281
- resilience, 34
- resistance, multidrug. *See* multidrug-resistance
- resource allocation, ethics and, 2, 3
- resource-limited settings
 - bacterial infections in, 252–256
 - bloodborne pathogens in, 260
 - disinfection in, 261
 - emerging pathogens in, 260–261
 - HAI in, 251
 - hand hygiene in, 261–262
 - infection control networks in, 262–263
 - MDRGNs in, 258
 - multidrug-resistance in, 257–258
 - Mycobacterium tuberculosis* in, 259–260
 - nosocomial infections in, 252–256
 - outbreaks in, 256
 - prevention programs in, 258–259
 - sterilization in, 261
 - tuberculosis in, 366–367
- respiratory hygiene, in outpatient setting, 241
- respiratory tract infections, 229
 - in LTCFs, 233
- retrospective cohort studies, 44–45
- ribosomal gene sequencing, 274
- rifampin, 373
- rifapentine, 373
- risk
 - assessment, 258
 - odds and, 45
 - relative, 45–46
 - risk communication, in biological disasters, 305
 - risk-specific rates, SSI, 154
 - Robert Wood Johnson Foundation (RWFJ), 32
 - RODS. *See* Real-Time Outbreak and Disease Surveillance
 - room, transmission-based precautions, 54
 - root cause analysis (RCA), 382–384, 385
 - Joint Commission on, 382–383
 - rubella, 4–5, 326–331
 - epidemiology of, 335
 - exposure workup, 334–335
 - laboratory evaluation, 350
 - vaccine, 334
 - vaccines, 352–353
 - rubella vaccine, 5
 - rubeola, 326–331
 - RWFJ. *See* Robert Wood Johnson Foundation
 - S. aureus*, 31, 101, 133, 156, 165
 - bacteremia, 95, 98
 - S. epidermidis*, 120–121
 - S. pettenkoferi*, 275
 - S. pyogenes*, 156
 - S. typhimurium*, 316
 - Saccharomyces, 204–205
 - safety, quality improvement and, 31
 - Safety Risk Assessment (SRA), 393
 - Salmonella*, 316
 - Sands, K., 152
 - SARS. *See* Severe Acute Respiratory Syndrome
 - saying no, learning how, 25–26
 - scabies, 326–331
 - exposure workups, 341
 - in LTCFs, 234
 - Schifman, R. B., 109
 - Schulman, J., 168
 - SCIP. *See* Surgical Care Improvement Project
 - self report, 84
 - semi-automated surveillance, 105
 - semicritical items
 - disinfectants, 61–64
 - storage of, 69
 - Semmelweis, Ignaz, 30, 92
 - SENIC. *See* Study on the Efficacy of Nosocomial Infection Control
 - sentinel event reporting, 385
 - serologic screening
 - laboratory evaluation and, 350
 - preplacement examination, 350
 - service expansion, BCA and, 25
 - service-specific rates, SSI, 154
 - Severe Acute Respiratory Syndrome (SARS), 75, 243, 252, 288–289, 325
 - as biological disaster, 320–321
 - CDC on, 342
 - diagnosis, 291–300
 - exposure workup, 342
 - incubation period, 342
 - prevention, 301–304
 - treatment, 306–312
 - vaccines, 306–312
 - sharp devices, in patient isolation, 53
 - sharps injury prevention, 21
 - Shaughnessy, M. K., 207
 - SHEA. *See* Society for Healthcare Epidemiology of America
 - shellac nail enhancements, 89
 - SICU. *See* surgical intensive care unit
 - silver alloy-coated urinary catheters, 137
 - single-use devices, 69
 - SIR. *See* standardized infection ratios
 - site visits, 419–420
 - site-specific infection, rates, 112
 - site-specific surveillance, 98
 - Sitzlar, B., 72–73
 - six-sigma, 33–34, 384
 - skilled nursing facilities (SNFs), 229
 - skin antisepsis, CLABSI and, 167
 - skin infections, 229
 - in LTCFs, 234
 - smallpox, 316
 - as bioterrorism agent, 317–319
 - diagnosis, 291–300
 - evaluation for, 318
 - exposure workups, 341–342
 - forms of, 317
 - prevention, 301–304
 - transmission of, 317
 - treatment, 306–312
 - vaccines, 306–312, 318
 - SNFs. *See* skilled nursing facilities
 - Society for Healthcare Epidemiology of America (SHEA), 10, 22–23, 82, 163, 180, 214, 232, 246, 251
 - on *C. difficile*, 203
 - on hand hygiene, 87
 - on HIV, 356–357
 - on infection control, 22–23
 - surveys from, 22–23
 - Society for Thoracic Surgeons (STS), 150–151
 - sodium hypochlorite, as disinfectant, 63, 64
 - soft tissue infections, 229
 - in LTCFs, 234
 - solidarity, Ebola and, 9
 - space shuttle disasters, 380
 - Spaulding, 58
 - special pathogens,
 - transmission-based precautions for, 55
 - specimen
 - collection and transport, 271–272
 - initial evaluation of, 272–273
 - spot maps, of outbreaks, 123
 - SRA. *See* Safety Risk Assessment
 - Srinivasan, A., 106–107
 - SSI. *See* surgical site infection
 - Stachybotrys chartarum*, 389
 - staffing, regulating, 425
 - stakeholders
 - CAUTIs and, 35
 - in infection prevention regulation, 418–419
 - outcome measures and, 37
 - on quality improvement, 32
 - standardized infection ratios (SIR), 36–37, 112, 147
 - SSI, 154
 - staphylococcal infections, 30–31
 - Starling, C., 252
 - state assets, 9
 - state governments, on oversight, 418
 - steam, advantages and disadvantages of, 62
 - sterile processing
 - representatives, 16
 - sterilization, 59
 - advantages and disadvantages of, 62
 - chemical agents for, 60–61
 - critical items, 58–61
 - of endoscopes, 64–65
 - exposure investigation after, 69
 - failures, 68
 - HPV and, 68–69
 - immediate use steam, 244
 - methods for, 59
 - noncritical items and, 64
 - in outpatient setting, 244
 - prions and, 74
 - rational approach to, 58
 - in resource-limited settings, 261
 - risks, 68
 - semicritical items, 61–64
 - storage areas, construction and, 407
 - strategic business plans, 25
 - Streptococcus pneumoniae*, 273
 - stress ulcers, 142–143
 - STS. *See* Society for Thoracic Surgeons
 - Study on the Efficacy of Nosocomial Infection Control (SENIC), 30–31, 147
 - publishing, 93
 - risk index, 150
 - on SSI, 149
 - on surveillance, 93

- subclavian vein, 167
for CVCs, 167
- supplemental oxygen, 157
- supplementary cultures, 277–279
- surface decontamination, 67–68
in outpatient setting, 241
- surgeon-specific rates, SSI, 154
- Surgical Care Improvement Project (SCIP), 156
- surgical intensive care unit (SICU), 150
- surgical services representatives, 16
- surgical site infection (SSI), 20, 93, 98, ix
adjusting for risk, 113
categorization of, 148
clinical evidence of, 151
data sources, 153–154
deep-incisional, 148
electronic surveillance of, 152
equations, 154
as HAIs, 104
intraoperative intervention, 157
IP, 113, 155
NNIS on, 254
objectives of surveillance, 147
100% chart review, 148–149
patient discharge and, 151
postdischarge surveillance, 151–152
postoperative intervention, 157
predictors for, 151
preoperative intervention, 156–157
prevention, 155–156
procedure-specific rates, 154
rates of, 147
reduction of, 257
reporting recommendations, 154–155
risk assessment, 149–150
risk factors, 153
risk-specific rates, 154
SENIC on, 149
service-specific rates, 154
SIR, 154
standard interventions, 156
surgeon-specific rates, 154
surveillance, 105, 113
surveillance methods, 148
wound examination, 148
- surveillance, 259
active cultures, 275–276
acute, 182–183
adjusting rates and, 112
advantages and disadvantages, 96–97
for ASPs, 94–97
assessment of, 97–101
automatic, 114–115
in biological disasters, 288–289
for *C. difficile*, 205
- of CAUTIs, 134–135
CDC on, 93
CLABSI, 164
CMS and, 149
communication of results of, 107
computer-based, 114–115
conducting, 94
data analysis in, 106–107
data collection in, 105–106
data management, 106
data sources for, 107–108
defining, 92–93
definitions in, 103–104, 147–148
in developing countries, 113–114
device exposure and, 113
electronic, 114–115, 152
fully automated, 105
for HAIs, 94–97, 108
of healthcare workers, 351
hospital-wide, 96–97, 108
information collection in, 98
IP on, 105
laboratory role in, 271
length of stay and, 112
in LTCF, 232
MDROs, 180–181, 275–276
methods, 97
MRSA, 275
needs, 101
NHSN and, 111–112
objective-based, 96–97, 109
objectives of SSI, 147
outcomes of interest in, 101–105
populations, 101–105
postdischarge, 111, 151–152
prevalence, 108
priorities, 97–101
priority-based, 109
for process measures, 113
process of, 93–94
program development, 95
public health, 315
regulatory requirements and, 114
selection of methods, 153
semi-automated, 105
SENIC, 93
site-specific, 98
SSI, 105, 113
summary of methods, 152–153
syndromic, 93
system requirements, 94, 95
targeted, 96–97, 109
threshold, 96–97
time demands, 97
of VAEs, 141–142
VAP, 140
- surveys, 419–420
CMS, 420
full, 420
Joint Commission, 420–421
OSHA, 422
partial, 420
- validation, 420
- susceptibility testing, 274–275
Suwantararat, N., 251–252
Sverdlovsk, 316
Swiss cheese model, 33, 382
SWOT analysis, 25
symptomatic bacteriuria, 134
syndromic surveillance, 93
system errors, 380
latent, 382
- tabular displays, 107
Tambyah, P. A., 133
targeted surveillance, 96–97
of HAIs, 109
Tartars, 316
TAT. *See* turnaround time
taxonomy, of ethical dilemmas, 2, 3
technology assistance, direct
observation with, 84
tetanus vaccine, 352–353
Texas Children's Hospital, 142
Thailand, 260, 261
threshold surveillance, 96–97
thrombocytopenia, 213
timeliness, quality improvement
and, 31
total chart review, 111
HAIs and, 110
total quality management, 30
toxigenic culture, 204
Toyota Production System (TPS), 384
traffic patterns, construction
and, 406–407
training, CLABSI, 168
transitions of care
ASPs and, 220
in LTCFs, 231
transmissible spongiform
encephalopathies (TSEs), 74
transmission-based precautions, 54
gloves in, 54
gown in, 54
masks in, 54
outpatient setting, 241
room, 54
for special pathogens, 55
syndrome-based approach to, 242
transparency, quality
improvement and, 31
Trichoderma, 389
Triclosan, 86
TSEs. *See* transmissible
spongiform
encephalopathies
tuberculin skin testing (TST), 233, 259–260
tuberculosis
administrative controls, 365–367
CDC on, 364–365, 372
education, 368
environmental controls, 368–369
- exposure, 363
extended care facilities, 368
extensively drug-resistant, 361
general ventilation and, 369
healthcare workers and, 367
hierarchy of controls, 365
IDSA on, 372–373
institutional controls in, 363–364
laboratory diagnosis of, 372
latent infection, 367, 368, 372–374
local exhaust ventilation and, 369
in LTCF, 233
multidrug-resistant, 361
nosocomial infections, 362, 363–364
OSHA on, 370–371
outbreaks, 361
in outpatient setting, 242–243
patient discharge in, 374
patient isolation for, 55
personal respiratory
protection and, 370–372
portable air filtration units
and, 369
prevention of, 363–364
in resource-limited settings, 366–367
responsibility in, 364
risk assessment, 364–365
screening for, 350–351
treatment of, 372–374
UVGI and, 369–370
WHO on, 361
- tularemia
as bioterrorism agent, 319
diagnosis, 291–300
mortality rate, 319
prevention, 301–304
treatment, 306–312
vaccines, 306–312
Turkey, 258
turnaround time (TAT), 273
typeability, 280, 281
- ultrasound
in CLABSI, 167
ultraviolet germicidal
irradiation (UVGI), 260
for *C. difficile*, 20, 21
cost effectiveness of, 21
tuberculosis and, 369–370
ultraviolet irradiation
advantages and disadvantages
of, 68
clinical trials, 70–71
hydrogen peroxide compared
with, 68
ultraviolet light, for
decontamination, 68
unintended effects, of patient
isolation, 56

Index

- United States, 30
 cleaning in, 66–67
United States Code (USC), 412
 University of Iowa, 9
 University of Maryland, 24
 University of North Carolina, 61
 unsafe injection practices, 128
 Upshur, R., 5
 urethral trauma, 136–137
 urinary catheters
 alternatives to, 136
 anti-infective, 137
 biofilms on, 133
 early removal of, 135–136
 indwelling, 135, 136
 insertion of, 136–137
 limitation of use of, 135–136
 maintenance of, 136–137
 medical records and, 136
 placement of, 136
 silver alloy-coated, 137
 urinary retention, perioperative management of, 136
 urinary tract infection (UTI), 93, 95, 133, 222. *See also* catheter-associated urinary tract infections
 descriptive epidemiology in, 133–134
 from Enterobacteriaceae, 133
 in LTCFs, 232–233
 microbial etiology of, 134
 pathogenesis of, 133
 urokinase, 171
 Ury, William, 25
 USC. *See United States Code*
 UTI. *See* urinary tract infection
 utility, 3, 9
 defining, 8
 Ebola and, 8
 UVGI. *See* ultraviolet germicidal irradiation
- vaccination
 ethical dilemmas and, 3–5
 for hepatitis B virus, 5
 influenza, 5
 pertussis, 4
 pregnancy and, 4–5
 rubella, 5
 vaccinations, for healthcare workers, 352–353
 VACs. *See* ventilator-associated conditions
 VAE. *See* ventilator-associated events
- validation surveys, 420
 value, in healthcare, 31–32
 value analysis, 24
 central position of, 18
 product evaluation and, 18
 value-based care programs, 423
 Value-Based Purchasing Program (VBP), 114
 vancomycin, 23–24, 213
 for *C. difficile*, 203–204
 vancomycin-resistant
 enterococci (VRE), 5, 10, 24, 27, 43, 64, 66, 95, 213, 252–256, 271, 272
 in case-control studies, 44
 contact precautions, 7
 control of, 6
 mechanism of resistance, 180
 patient isolation for, 6, 56
 risk factors, 6
 spread of, 5–6
 transmission, 180
 vancomycin-resistant *S. aureus* (VRSA), 178–180
 VAP. *See* ventilator-associated pneumonia
 vaporized hydrogen peroxide, advantages and disadvantages of, 62
 variant Creutzfeldt-Jakob disease (vCJD), 338
 varicella
 laboratory evaluation, 350
 vaccine, 352–353
 varicella zoster, 1, 326–331
 exposure workups, 333–334
 incidence of, 333
 VBP. *See* Value-Based Purchasing Program
 vCJD. *See* variant Creutzfeldt-Jakob disease
 Venkatram, S., 168
 ventilator-associated conditions (VACs), 142
 ventilator-associated events (VAE), 140
 CDC on, 142
 in children, 142
 classification of, 141
 clinical correlates, 143
 definitions, 140–141
 iatrogenic events and, 143
 incidence of, 141
 intervention trials, 143–145
 morbidity, 141
 mortality, 141
 in neonates, 142
 prevention of, 142–143
 rates of, 144
 risk factors, 143
 surveillance of, 141–142
 technical definition, 140–141
 ventilator-associated pneumonia (VAP), 93, 140, 251
 classifications, 140
 clinical rates, 140
 incidence of, 253–254
 NHSN on, 140
 possible, 141
 rates, 144–145
 surveillance, 140
 Verona integron-encoded metallo- β -lactamase (VIM), 191–192
 Veterans Affairs, 234
 Veterans Health Administration (VHA), 22
 VHF. *See* viral hemorrhagic fever
 Vienna, 30
 VIM. *See* Verona integron-encoded metallo- β -lactamase
 viral hemorrhagic fever (VHF)
 as bioterrorism agent, 320
 diagnosis, 291–300
 early identification of, 314
 prevention, 301–304
 treatment, 306–312
 vaccines, 306–312
 viral hepatitis, 128
 visitors
 airborne precautions and, 56
 contact precautions and, 56
 droplet precautions and, 56
 patient isolation and, 56
 VRE. *See* vancomycin-resistant enterococci
 VRSA. *See* vancomycin-resistant *S. aureus*
- Wake Forest University, 218
 walls, construction of, 404–405
 Warren, D. K., 113
 waste, 404
 water guidelines, 391–392
 water supply, 403–404
 Weber, S., 168
 Wenzel, R. P., 151
 West Africa, Ebola in, 8
 WGS. *See* whole genome sequencing
 white blood cell count, 205
 whole genome sequencing (WGS), 126, 280–281
 WIFI, 83
 Wisniewski, M. F., 114–115
 Workbook for Designing, Implementing, and Evaluating a Sharps Injury Prevention Program
 data in, 19–20
 financial impact analysis in, 20
 information gathering in, 19
 post-implementation monitoring, 20
 priorities in, 19
 product evaluation surveys, 19
 product information in, 19
 product selection in, 20
 selection criteria in, 19
 team organization in, 19
 World Bank, 251
 World Health Organization, 32, 82, 156, 288–289
 on cost effectiveness, 24
 on hand hygiene, 82–83
 observation forms, 87
 on tuberculosis, 361
 World War I, 316
 World War II, 30, 319
 wound classification, 149, 150
 wound examination, SSI, 148
 wound sepsis, 147
 postsurgical, 381–382
 XDR-TB. *See* extensively drug-resistant tuberculosis
 Xpert MTB/RIF assay, 366, 372
 Yaw, L. K., 177–178
 Zika virus, 412–417
 Zingg, W., 168